Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Pharmacological Management of Type 2 Diabetes Mellitus: An Update
复制标题
DOI：
10.2174/157339911797579160
复制
发表时间：
2011-01-01
影响因子：
3.3
通讯作者：
Sherbeeni, Suphia
中科院分区：
文献类型：
--
作者：
El-Kaissi, Samer;Sherbeeni, Suphia
虽然生活方式改变和二甲双胍是2型糖尿病初始管理的基石，但用于这种疾病的二线和三线药物越来越多。这些药物包括磺脲类、胰岛素、噻唑烷二酮类和α-葡萄糖苷酶抑制剂，最近增加了胰高血糖素样肽-1激动剂、二肽基肽酶-IV抑制剂和普兰林肽。此外，已经开发了更好地模拟内源性胰岛素分泌的胰岛素类似物。本文综述了目前2型糖尿病药物治疗的最新进展，并强调了每种治疗方法的优点和局限性。
While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagonlike peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.